ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317

Also written as “BNT317 DL1”, “BNT317 DL2” and “BNT317 DL3”.

Its studies are mostly in Carcinoma, Renal Cell, led by BioNTech.

Furthest: phase 2, since Dec 12, 20241 company-led study, 1 open or runningNext primary completion: Apr 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech11 open or runningphase 2since Dec 12, 2024Dec 12, 2024Apr 2031phase 2 · NCT06750185

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2024First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT06750185 · 248 planned · United States, Australia

Ahead

  1. Apr 2031Primary completion: phase 2 study in Carcinoma, Renal CellNCT06750185

TargetBeta

“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06750185Carcinoma, Renal Cell · United States, Australia2RecruitingApr 2031248

How it is read

Names in the registry

  • “BNT317 DL1”, 1 entry
  • “BNT317 DL2”, 1 entry
  • “BNT317 DL3”, 1 entry
  • “BNT317 DL4”, 1 entry
  • “BNT317 DL5”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.